Main

Fields of interest:

• Cardiovascular genomics

Recent publications:

S.R. Steinhubl, P.B. Berger, J.T. Mann, E.T.A. Fry, A. DeLargo, C. Wilmer, E.J. Topol, for the CREDO Investigators:
Early and sustained dual oral antiplatelet therapy for percutaneous coronary intervention: results of the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial.
Journal of the American Medical Association, Vol. 288, 2002, pp. 2411-2420.

Q. Wang, S. Rao, G.-Q. Shen, L. Li, D. Moliterno, L.K. Newby, W.J. Rogers, R. Cannata, E. Zirzow, R.C. Elston, E.J. Topol: Premature myocardial infarction novel susceptibility locus on chromosome 1p34-36 identified by genome-wide linkage analysis.
American Journal of Human Genetics, Vol. 74, 2004, pp. 262-271.

L. Wang, C. Fan, S.E. Topol, E.J. Topol, Q. Wang: Mutation of MEF2A in an inherited disorder with features of coronary artery disease.
Science, Vol. 302, 2003, pp. 1578-1581.

M.R.K. Bhagavatula, C. Fan, G.-Q. Shen, J. Cassano, E.F. Plow, E.J. Topol, Q. Wang: Transcription factor MEF2A mutations in patients with coronary artery disease.
Human Molecular Genetics, Vol. 13, 2004, pp. 3181-3188.

A.M. Lincoff, N.S. Kleiman, D.J. Kereiakes, F. Feit, J.A. Bittl, J.D. Jackman, I.J. Sarembock, D.J. Cohen, D. Spriggs, R. Ebrahimi, G. Keren, J. Carr, E.A. Cohen, A. Betriu, W. Desmet, W. Rutsch, R.G. Wilcox, P. de Feyter, A. Vahanian, E.J. Topol, for the REPLACE-2 Investigators:
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade versus heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization. REPLACE-2 Randomized Trial.
Journal of the American Medical Association, Vol. 292, 2004, pp. 696-703.

J.J. McCarthy, A. Parker, D.J. Moliterno, R. Salem, Q. Wang, E.F. Plow, S. Rao, G.-Q. She, W.J. Rogers, L.K. Newby, R. Cannata, K. Glatt, E.J. Topol, for the GENEQUEST Investigators:
Large-scale association analysis for identification of genes underlying premature coronary heart disease: Cumulative perspective from analysis of 111 candidate genes.
Journal of Medical Genetics, Vol. 41, 2004, 334-341.

A. Helgadottir, A. Manolescu, G. Thorleifsson, S. Gretarsdottir, H. Jonsdottir, U. Thorsteinsdotttir, N.J. Samani, G. Gudmundsson, S.F.A. Grant, G. Thorgeirsson, S. Sveinbjornsdottir, E.M. Valdimarsson, S.E. Matthiasson, H. Johannson, O. Gudmundsdottir, M.E. Gurney, J. Sainz, M. Thorhallsdottir, M.L. Frigge, E.J. Topol, A. Kong, V. Gudnason, H. Hakonarson, J.R. Gulcher, K. Stefannson: The gene encoding 5-liopoxygenase activating protein confers risk of myocardial infarction and stroke.
Nature Genetics, Vol. 26, 2004, pp. 223-239.

H. Hakonarson, S. Thorvaldsson, A. Helgadottir, D. Gudbjartsson, F. Zink, M. Andresdottir, A. Manolescu, D.O. Arnar, K. Andersen, A. Sigurdsson, G. Thorgeirsson, A. Jonsson, U. Agnarsson, H. Bjornsdottir, G. Gottskalksson, A. Einarsson, H. Gudmundsdottir, A.E. Adalsteinsdottir, K. Gudmundsson, K. Kristjansson, T. Hardarson, A. Kristinsson, E.J. Topol, J. Gulcher, A. Kong, M. Gurney, G. Thorgeirsson, K. Stefansson: Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial,
Journal of the American Medical Association, Vol. 11(293), 2005, pp. 2277-2279.

E.J. Topol: The genomic basis of myocardial infarction.
Journal of the American College of Cardiology, Vol. 46, 2005, pp. 1456-1465.

A. Helgadottir, A. Manolescu, A. Helgason, G. Thorleifsson, U. Thorsteinsdottir, D. Gudbjartsson, S. Gretarsdottir, K.P. Magnusson, G. Gudmundsson, A. Hicks, T. Jonsson, S.F.A. Grant, J. Sainz, S.J. O’Brien, S. Sveinbjornsdottir, E.M. Valdimarsson, S.E. Mattiasson, A.I. Levey, G. Thorgeirsson, J.L. Abramson, M. Reilly, V. Vaccarino, M. Wolfe, V. Gudnason, A.A. Quyyumi, E.J. Topol, D. Rader, J. Gulcher, H. Hakonarsson, A. Kong, K. Steffansson: A variant of the gene encoding Leukotriene A4 Hydrolase confers ethnic specific risk of myocardial infarction.
Nature Genetics, Vol. 38, 2006, pp. 68-74.

D.L. Bhatt, K.A.A. Fox, W. Hacke, P.B. Berger, H.R. Black, W.E. Boden, P. Cacoub, E.A. Cohen, M.A. Creager, J.D. Easton, M.D. Flather, S.M. Haffner, C.W. Hamm, G.J. Hankey, S.C. Johnston, K.H. Mak, L.J. Mas, G. Montalescot, T.A. Pearson, P.G. Steg, S.R. Steinhubl, M.A. Weber, D.M. Brennan, L. Fabry-Ribaudo, J. Booth, E.J. Topol for the CHARISMA Investigators:
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
New England Journal of Medicine,
Vol. 354, 2006, pp. 1706-1717.